SVT-40776 in Patients Suffering From Overactive Bladder Syndrome

• Status: Completed
• Trial end date: 2007-09-01
• Target enrollment: 0
• Participant gender: All

Summary

The study will examine which dose of SVT-40776 is best in terms of efficacy, safety and tolerability compared to placebo and tolterodine

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Salvat

Criteria

Inclusion Criteria:

• Patients suffering from OAB for at least 6 months prior to inclusion

Exclusion Criteria:

• Pregnant and breastfeeding women

• Any medical condition or need for co-medication which interferes with the drug under investigation (SVT-40776) or the comparator (tolterodine)